The Debate

We will introduce why and how we are at point of controversies today. The opening debate will explore whether a genetic-driven approach just needs more time to produce results or whether we need to first invest more in a regulatory filtering of genetic variations.

WELCOME FROM SUMMIT CHAIRPERSON 
Dan Peer
Director, Tel Aviv University Cancer Biology Research Center, Tel Aviv, Israel

danp.JPG


OPENING ADDRESS
Martin Lohse
Chair of the Board of Directors and Scientific Director of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association Member of the Board of Directors of the Berlin Institute of Health (BIH), Berlin, Germany 

Martin Lohse.jpg
Richard FitzGerald (1).jpg
Richard FitzGerald 
Director, Clinical Research Unit, RLUH, Liverpool, UK 

Same Medicine, Different Results - the Impact of Personalised Medicine

The talk will highlight the origins and rationale behind personalised medicine, its current reach and the potential for personalised medicine to transform the way care is delivered to patients over the next two decades. 
Denis Noble-resized.jpg
Denis Noble 
Emeritus Professor 
of Cardiovascular Physiology, Oxford, UK

Regulatory Filtering of Genetic Variation: Why GWAS Outcomes so far are Disappointing

The influence of variations in DNA sequences on the phenotype is strongly filtered by regulatory networks at higher levels (cells, tissues, organs, systems). This is the main reason why GWAS research has produced relatively disappointing outcomes in terms of correlations with health and disease. It is now far from certain that extending such studies to much larger cohorts will solve the problem. The solution may be to switch to understanding better the filtering by regulatory networks. 

To read a Q&A with Prof. Noble, click here

To download the full programme, click here.

Back>>